Gsk (GSK) Cash from Investing Activities (2009 - 2026)

Gsk's Cash from Investing Activities history runs 18 years deep, the most recent figure standing at $2.7 billion for Q2 2026.

• In Q2 2026, Cash from Investing Activities rose 78.1% year-over-year to $2.7 billion; the TTM figure through Jun 2026 stood at $27.1 million (down 99.09% YoY), while the FY2025 annual figure was -$5.6 billion, down 255.27% from the prior year.
• Cash from Investing Activities for Q2 2026 stood at $2.7 billion, up from -$2.0 billion in the prior quarter.
• The five-year high for Cash from Investing Activities was $4.2 billion in Q4 2023, with the low at -$4.9 billion in Q4 2022.
• The 5-year median for Cash from Investing Activities is $424.7 million (2023), against an average of -$11.9 million.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities slumped 7184.1% in 2022, then jumped 262.83% in 2025.
• Gsk's Cash from Investing Activities stood at -$4.9 billion in 2022, then jumped by 187.17% to $4.2 billion in 2023, then slumped by 71.97% to $1.2 billion in 2024, then tumbled by 298.41% to -$2.4 billion in 2025, then surged by 213.69% to $2.7 billion in 2026.
• Business Quant data shows GSK's Cash from Investing Activities at $2.7 billion in Q2 2026, -$2.0 billion in Q1 2026, and -$2.4 billion in Q4 2025.